Quantum Critical Metals has launched an advanced mineral mapping program using historical samples from its Discovery Property in Québec to identify mineral hosts of gallium, rubidium, and other critical minerals. This study aims to guide future metallurgical testing and processing by understanding the mineralogy and metal distribution without new drilling. Results will help focus exploration and recovery methods, with next steps including detailed assays and potential flotation testing. The company also held a successful annual general meeting confirming its board and auditor for 2026.
Quantum Critical Metals' advanced mineral mapping in Québec is the subject, with Pluang data providing market context. For readers following Basic Materials, 24 of 34 US stocks rose and 7 fell today. Notable movers include TECK at USD 67.47 (+2.98%), ALB at USD 114.03 (+2.81%), and LAC at USD 2.92 (+2.10%). This snapshot is as of Sep 21, 2026 18:51 WIB.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Faruqi & Faruqi, LLP is investigating claims against Ardelyx for allegedly misleading investors about the commercial performance of its drugs XPHOZAH and IBSRELA. The lawsuit alleges Ardelyx failed to disclose increasing payer restrictions that hurt ...
